...
首页> 外文期刊>European review for medical and pharmacological sciences. >Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway
【24h】

Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway

机译:长时间非编码RNA DLX6-AS1的下调定义了良好的预后并通过Notch信号通路抑制了人类上皮性卵巢癌细胞的增殖和转移

获取原文

摘要

OBJECTIVE: Long noncoding RNAs (lncRNAs) are key regulatory RNAs which take(s) part in several biological processes. Recently, a newly identified lncRNA, long noncoding RNA DLX6-AS1 (DLX6-AS1), was reported to be involved in the progression of several tumors. However, its expression and biological function in epithelial ovarian cancer (EOC) have not been investigated. The present study aimed to investigate the role of DLX6-AS1 in the development and progression of EOC. PATIENTS AND METHODS: The expression levels of DLX6-AS1 in EOC tissues and cells were detected by reverse transcriptase-polymerase chain reaction (RT-PCR). The association between DLX6-AS1 expression and clinicopathologic characteristics and prognosis in patients with EOC was statistically analyzed. Subsequently, loss-of-function assays were performed to explore alterations in a series of cells phenotypes, including cell viability, colony formation, cell cycle, apoptosis, colony formation, and migration and invasion capacities. The effect of DLX6-AS1 on the Notch signaling pathway was evaluated by Western blot and RT-PCR. RESULTS: We first verified the increased expression of DLX6-AS1 in EOC patient samples and cell lines. Clinical assays indicated that high DLX6-AS1 was significantly associated with FIGO stage, lymph node metastasis and poor prognosis. Furthermore, multivariate Cox regression analysis confirmed DLX6-AS1 as an independent prognostic factor in EOC patients. Functionally, the down-regulation of DLX6-AS1 decreased EOC cells proliferation, migration, invasion and induced cell cycle G1/S phase arrest and cell apoptosis. Mechanistic studies revealed that the knockdown of DLX6-AS1 down-regulated Notch1, p21, and Hes1, indicating that the activity of the Notch signaling pathway was inhibited. CONCLUSIONS: Our results demonstrated that DLX6-AS1 inhibited a tumor-promoting role in EOC and may be useful as a prognostic biomarker and/or a therapeutic avenue for EOC.
机译:目的:长非编码RNA(lncRNA)是参与多个生物学过程的关键调控RNA。最近,据报道新鉴定的lncRNA,长的非编码RNA DLX6-AS1(DLX6-AS1)与几种肿瘤的进展有关。但是,尚未研究其在上皮性卵巢癌(EOC)中的表达和生物学功能。本研究旨在调查DLX6-AS1在EOC发生和发展中的作用。病人与方法:通过逆转录-聚合酶链反应(RT-PCR)检测DLC6-AS1在EOC组织和细胞中的表达水平。统计学分析DLC6-AS1表达与EOC患者的临床病理特征和预后之间的关系。随后,进行功能丧失测定以探索一系列细胞表型的改变,包括细胞活力,集落形成,细胞周期,细胞凋亡,集落形成以及迁移和侵袭能力。通过蛋白质印迹和RT-PCR评估了DLX6-AS1对Notch信号通路的影响。结果:我们首先验证了EOC患者样品和细胞系中DLX6-AS1表达的增加。临床分析表明,高DLX6-AS1与FIGO分期,淋巴结转移和不良预后显着相关。此外,多因素Cox回归分析证实DLX6-AS1是EOC患者的独立预后因素。在功能上,DLX6-AS1的下调降低了EOC细胞的增殖,迁移,侵袭并诱导了细胞周期G1 / S期阻滞和细胞凋亡。机理研究表明,敲低DLX6-AS1会下调Notch1,p21和Hes1,表明Notch信号通路的活性受到抑制。结论:我们的结果表明DLX6-AS1抑制EOC中的肿瘤促进作用,并可能用作EOC的预后生物标志物和/或治疗途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号